-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Dqoj1lStuUpTz2AFqwlTlv5gVPG+DwNzRPcKG1+tsUwdrtoA7ayLUwrTqPoj0Yty 4DooCQtxK1gWfUbGiopINg== 0000914475-06-000002.txt : 20060123 0000914475-06-000002.hdr.sgml : 20060123 20060123201158 ACCESSION NUMBER: 0000914475-06-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060119 FILED AS OF DATE: 20060123 DATE AS OF CHANGE: 20060123 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LYONS GARY A CENTRAL INDEX KEY: 0001123343 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 06544789 BUSINESS ADDRESS: STREET 1: 10555 SCIENCE CENTER DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8586177600 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL STREET 2: C/O NEUROCRINE BIOSCIENCES CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2006-01-19 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001123343 LYONS GARY A NEUROCRINE BIOSCIENCES, INC. 12790 EL CAMINO REAL SAN DIEGO CA 92130 1 1 0 0 President and CEO Stock Option 60.95 2006-01-19 4 A 0 60000 60.95 A 2006-02-19 2013-01-19 Common Stock 60000 60000 D Restricted Stock Units 2006-01-19 4 A 0 20000 0 A Common Stock 20000 20000 D Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 19, 2006 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Each restricted stock unit represents a contingent right to receive one share of Neurocrine Common Stock. The restricted stock units will vest monthly at 1/36th of the units beginning February 19, 2006. Vested shares will be delivered to the reporting person in January following the year in which the reporting person terminates employment with Neurocrine. Margaret E. Valeur-Jensen, By Power of Attorney 2006-01-23 -----END PRIVACY-ENHANCED MESSAGE-----